Company achieved FDA alignment on Phase 3 Oz-V trial for the treatment of 2L+ OPSCC, which will evaluate dual primary ...

Vaxart secures major Dynavax deal, extending cash runway to 2027. Get Q3 earnings insights, clinical progress, and outlook on innovative oral vaccines.

The aim is to find new uses of real-world data in AI development, and to help health systems move from fragmented, compliance ...

Ancient Egyptian gods influence daily energies, guiding individuals toward clarity, strength, and cosmic validation. Each ...

Astrology offers insights into personal well-being for November 13, 2025. Each zodiac sign receives tailored advice, ...

On track to submit GraftAssureDx™ for FDA review by year-endOn track for commitment to have 20 transplant centers globally engaged with GraftAssure technology by end of 2025GraftAssure assay’s head-to ...

Q3 2025 Earnings Call November 13, 2025 5:00 PM ESTCompany ParticipantsKelly Goodman - Interim CEO & Corporate ...

PolyPid Ltd. (NASDAQ: PYPD) Q3 2025 Earnings Call Transcript November 12, 2025 PolyPid Ltd. beats earnings expectations.

Capital raised -- $17.1 million in new funding was secured, including a $13 million post-quarter investment from a leading ...

Learn how the European Union’s Corporate Sustainability Reporting Directive (CSRD) is designed to enhance the transparency of ...

IPPs (Independent power producers): Companies that own and operate power generation facilities, selling electricity to ...

Security leaders are under increasing pressure to prove that their defenses actually work. Board members and stakeholders want to see measurable progress, yet most metrics available to CISOs today don ...